GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA
2023-02-23
疫苗细胞疗法信使RNA
Preview
来源: Pharmaceutical Technology
GenScript ProBio will offer GMP plasmid manufacturing service to manufacture RVAC Medicines’ mRNA Covid-19 vaccineCovid-19 vaccine candidate. Credit: Spencer Davis / Unsplash.
Preview
来源: Pharmaceutical Technology
GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate.
Under the agreement, GenScript ProBio will offer GMP plasmid manufacturing service for the RVM-V001 programme.
This collaboration is expected to help expedite the clinical manufacturing of RVM-V001 and future mRNA-based vaccines that target infectious diseases such as Clostriodioides difficile infection (CDI) and Respiratory syncytial virus (RSV).
GenScript ProBio CEO Dr Brian Min said: “We are delighted to enter into this strategic partnership with RVAC Medicines.
“This collaboration will enable us to utilise our cutting-edge GMP plasmid manufacturing platform technology to support the development of mRNA-based Covid-19 vaccine and its therapeutic candidates.”
The company provides end-to-end contract development and manufacturing organisation (CDMO) services from the discovery to the commercialisation of drugs.
It continues to offer GMP materials, including plasmid DNA and the ancillary materials development for supporting the mRNA manufacturing process, as RVAC advances its mRNA candidates’ development.
The GenScript ProBio team also offers consultative and expert guidance concerning the regulatory and quality expectations of agencies globally.
To support the mRNA initiatives, RVAC Medicines will continue to partner with GenScript ProBio for the clinical-stage development and commercial stage of its candidates.
RVAC Medicines CEO Dr Sean Fu said: “We are excited to work closely with GenScript ProBio. With its technical strength and customer-centric approach, GenScript ProBio will help to accelerate the development of RVAC’s pipeline.”
In July last year, GenScript ProBio and ACT Therapeutics entered a strategic collaboration memorandum of understanding (MoU) to develop a next-generation chimeric antigen receptor (CAR)-T cell therapy platform.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
Preview
来源: Pharmaceutical Technology
By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy
By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。